Form 4: Artivion Director James Bullock Receives Stock Grant

Director James Bullock was granted 7,576 shares of Artivion common stock as part of an equity incentive plan.

Summary

• Director James Bullock acquired 7,576 shares of Artivion, Inc. (AORT) common stock.
• The transaction occurred on May 18, 2026.
• The shares were granted at a price of $0, representing a restricted stock award (RSA).
• Following this transaction, James Bullock's total beneficial ownership is 76,223 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• The grant aligns the director's interests with those of shareholders through equity ownership.

Negatives

• None identified.

Risks

• The vesting of these shares is subject to the terms of the Equity and Cash Incentive Plan, which may be impacted by future company performance or policy changes.

Future Outlook

The shares are scheduled to vest on May 18, 2027, subject to the terms of the company's Equity and Cash Incentive Plan.

Industry Context

StockSavvy.ai notes that director equity grants are standard corporate governance practices designed to incentivize long-term leadership commitment and align management with shareholder interests.

Comparison to Industry Standards

• The grant of restricted stock units (RSUs) to non-employee directors is a common practice among mid-cap medical device companies to ensure retention and alignment.
• The vesting period of one year is consistent with standard industry practices for annual director equity compensation.

Stakeholder Impact

• Shareholders may view the increased equity stake of a director as a positive sign of confidence in the company's long-term prospects.

Next Steps

• Vesting of the 7,576 shares on May 18, 2027.

Key Dates

Keywords

Artivion, AORT, Form 4, Insider Trading, Director Compensation, Equity Incentive Plan